Nilotinib: In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

By Garnock-Jones Karly P.  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1579-1590

Adis International

Access to resources Recommend Favorite

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

By Shimoni Avichai   Volchek Yulia   Koren-Michowitz Maya   Varda-Bloom Nira   Somech Raz   Shem-Tov Noga   Yerushalmi Ronit   Nagler Arnon  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 863-871

Blackwell Publishing

Access to resources Recommend Favorite

Dasatinib: A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By McCormack Paul L.   Keam Susan J.  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1771-1795

Adis International

Access to resources Recommend Favorite

Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia - is it all BCR-ABL?

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 3-19

Bentham Science Publishers

Access to resources Recommend Favorite

The expanding role of nilotinib in chronic myeloid leukemia

By Kim Theo Daniel   Coutre Philipp le  

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 97-107

Informa Healthcare

Access to resources Recommend Favorite